

Index

a

Acanthopanax senticosus (ASSL) 192
 Aconiti Kusnezoffii Radix 211
 active ingredients 175, 176, 199, 201,
 205–212
 alcoholic liver injury (ALI) 189
 alpha-fetoprotein (AFP) 114
 Alzheimer's disease (AD) 87, 135, 148,
 175, 206, 230
 antihypertensive drug digoxin 199
 arginine/kynurenine ratio 163
Artemisia annua (*Asteraceae*) 171, 199
 artemisinin 171, 199

b

bile acids (BAs) 148
 bio-fluids in metabolomics 34
 biological data sets 99, 100
 biological metabolites 99

c

camptothecin 171
 cancer management, HCC
 epidemiology and diagnosis 114
 metabolomics screening biomarkers
 117
 non-symptoms 113
 primary malignant liver tumor 113
 prospective biomarkers 114–116
 capillary electrophoresis (CE) 22
 capillary electrophoresis-mass
 spectrometry (CE-MS) 24, 48

cardiovascular disease (CVD) 148, 171,
 172, 192, 225
 central nervous system (CNS) diseases
 clinical diagnosis of 138
 CSF sampling 136
 current status and potential
 applications of 137
 Huntington's Disease (HD) 136
 cerebrospinal fluid (CSF) 35, 88, 135
 chemical derivatization method 227
 chinmedomics strategy 175, 209, 210
 cholangiocarcinoma (CCA) 88, 148
 cholesterol 223
 cholesteryl esters 128
 chromatography platform
 capillary electrophoresis (CE) 22
 gas chromatography technique 21
 liquid chromatography technique 21
 supercritical fluid chromatography
 (SFC) 22
 Clerodendranthi Spicati Herba (CSH)
 176
 cognitively normal controls (Ctrl) 137
 coronary heart disease (CHD)
 biomarker dilemma 127–128
 biomarker discovery 123, 125
 diagnosis and medical therapy of 123
 disease progress 123–124
 early diagnosis and interventional
 therapy 129
 gold standard methods 126
 herbal medicine treatment 128–129

coronary heart disease (CHD) (*contd.*)

- lipid metabolism 128
- metabolic pathways 126
- metabolomic profiling 126
- metabolomics analytical system and modern techniques 126
- metabolomic signatures 126
- pathological mechanism of 129
- pathomechanism exploration 123–124

coronavirus disease 2019 163

CSF sampling 136

d

Danggui Buxue Decoction (DBD) 254

Danggui Sini decoction 189

desorption electrospray ionization (DESI) 251

direct analysis in real time (DRAT) 51

direct infusion-mass spectrometry (DI-MS) 49, 50

disease diagnoses and metabolism 4, 6

disease mechanism 73

disease phenotypes 33

Dohongsamul-tang (DST) 254

drug discovery 176

drug efficacy 7

e

early biomarkers for disease 82

early childhood caries (ECC) 147

early diagnosis of diseases 67, 73

electrospray ionization mass spectrometry (ESI/MS) 250

endogenous metabolites 137

Eomecon chionantha Hance (ECH) 175

ethanol extract of epimedium (Ext-epi) 192

f

fatty acid extraction and derivatization process 226

Folium Artemisiae Argyi (mugwort) 176

food science 231

g

gas chromatography-mass spectrometry (GC-MS) 23, 46, 103–104, 203

gas chromatography technique 21

geniposide 207

glycerolipids 128

gold standard methods, CHD 126

GS-MS 104

Guan-Xin-Jing capsule (GXJC) 193

h

heatmap 82, 84

heatmap visualization 54–55

helium 51

hepatitis B-related HCC 117

hepatitis B virus (HBV) 114

hepatocellular carcinoma (HCC)

epidemiology and diagnosis 114

metabolomics screening biomarkers 117

non-symptoms 113

primary malignant liver tumor 113

prospective biomarkers 114–116

herbal medicine (HM)

application 175–176

artemisinin 171

camptothecin 171

chemical composition of 199

chemicals and pharmacological properties of 172

chinmedomics strategy 175

definition 171

discovery of quality-markers 209

disease treatment 172

high-throughput analysis 209

metabolomics

biomarkers 186, 189

dissection 186

effect evaluations 189

horizontal cluster analysis 186, 188

mechanism explorations 192–193

metabolic pathway analysis 186, 191

metabolite enrichment analysis 186, 190

- metabolite fingerprint 186, 188
 - principal component analysis
 - 185–186
 - quality control of 193–194
 - tree cluster analysis 185, 187
 - nuclear magnetic resonance
 - spectroscopy (NMR) 173
 - paclitaxel 171
 - precision medicine 148–150
 - reveal efficacy 208
 - silibinin 171
 - treatment 128
 - in vivo* processes 173–175
 - herbal preparation (HP) 171
 - Huanglian Jiedu* decoction 203
 - Huangqi Jianzhong Tang (HJZT) 192
 - Huntington's Disease (HD) 136
 - hydrophilic interaction chromatography
 - (HILIC) 47, 227
 - hydroxypurine 117
 - hyperlipidemia 232
- i**
- ion mobility-mass spectrometry (IM-MS)
 - 49
 - ion-pairing liquid chromatography (IPLC)
 - 47
- j**
- Jian-Pi-Yi-Shen formula (JPYSF) 192
- k**
- Kaixin San (KXS) 175
 - Keluoxin (KLX) capsule 253
 - kynurenine/tryptophan ratio 136
- l**
- lipid metabolism 128
 - lipidomics 246
 - analysis 128
 - biomarker discovery 229–230
 - clinical biomarker discovery 232
 - definition 223
 - efficacy analysis 230–231
 - flow chart of 224
 - food science 231
 - future aspect 233
 - gas chromatography-mass spectrometry
 - 228
 - ion mobility mass spectrometry (IMS)
 - 228–229
 - liquid chromatography-mass
 - spectrometry 227–228
 - mass spectrometry imaging technology
 - 229
 - non-targeted lipidomics 225
 - omics technology 223
 - pharmacological research 232
 - sample preparation 225–227
 - shotgun lipidomics 229
 - supercritical fluid
 - chromatography-mass
 - spectrometry 228
 - targeted technology 224–225
 - toxicology analysis 232–233
 - lipids 223
 - liquid chromatography-mass
 - spectrometry (LC-MS) 24, 102, 103
 - HILIC 47–48
 - metabolomics analyses 69–71
 - reversed-phase liquid
 - chromatography-mass
 - spectrometry 47
 - SFC-MS 48
 - liquid chromatography technique
 - 21–22
- m**
- macroalbuminuric diabetic kidney
 - disease 4
 - mass spectrometry (MS)-based lipidomics
 - classical method 246–247
 - data collection and analysis of
 - pseudotargeted lipidomics 249–250
 - targeted lipidomics 249
 - untargeted lipidomics 248–249
 - green technologies 247–248
 - herbal medicine 253–254
 - ionization technology 250–251

- mass spectrometry (MS)-based lipidomics (*contd.*)
 - ion mobility mass spectrometry (IM-MS) 252–253
 - mass analyzer 251–252
 - mass spectrometry imaging 253
 - tandem mass spectrometry 252
- mass spectrometry (MS) based
 - metabolomics
 - application 37–38
 - biological function analysis
 - advances in 158–159
 - correlation network analysis 160, 162
 - disadvantages 165
 - disease phenotype 158
 - fingerprint chromatogram 159
 - future perspective 165
 - K-means feature clustering 160–161
 - mass spectrometry instrumentation 159
 - metabolic network analysis 164
 - metabolic pathways 160, 163
 - partial least squares pattern recognition 160–161
 - principal component pattern recognition 160
 - disease diagnoses and metabolism 4–6
 - drug efficacy 7
 - GC-MS 103–104
 - LC-MS 102–103
 - metabolic fingerprinting and profiling 98
 - metabolic mechanism 6–7
 - metabolite identification bottleneck 99–101
 - metabolites and metabolic pathway
 - applications 70–73
 - biomarker discovery 69
 - biomarker identification 70
 - data extraction and analysis for 69–70
 - NMR-MS 104–105
 - non- or targeted metabolomics 99
 - nutrition 7–8
 - plant biology 8
 - prospects 105
 - quality control bottleneck 101–102
 - sample collection and storage
 - CSF analysis 35
 - plasma and serum 35
 - saliva 36
 - tissue homogenates 35–36
 - urine 34–35
 - sample preparation and processing 36–37
- mass spectrometry imaging (MSI) 50–51
- mass spectrometry (MS) platform
 - CE-MS 24
 - GC-MS 23
 - LC-MS technique 24
 - SFC-MS technique 24
- matrix assisted laser desorption ionization (MALDI) 50, 250
- metabolic fingerprint 20, 98
- metabolic mechanism 6, 7
- metabolic profiling 98
- metabolites
 - identification bottleneck 99
 - physical and chemical properties of 45
- metabolome 34, 36
- metabolomics
 - for biomarker discovery 82–83
 - challenges in 88
 - chromatography platform
 - capillary electrophoresis (CE) 22–23
 - gas chromatography technique 21
 - liquid chromatography technique 21–22
 - supercritical fluid chromatography (SFC) 22
 - comprehensive and multi-dimensional analytical platform techniques 25
 - in coronary heart disease 135
 - current analytical technologies of 20
 - definition 1
 - definition 200

- disadvantages 8
 - future development 38
 - loadings (molecules) analysis 2, 3
 - mass spectrometry (MS) 2
 - mass spectrometry platform
 - CE-MS 24
 - GC-MS 23
 - LC-MS technique 24
 - SFC-MS technique 24
 - for mechanism interpretation 83–85
 - metabolic network change mechanism
 - 2, 6
 - metabolic pathway 2, 4
 - MS-based metabolomics methods
 - disease diagnoses and metabolism
 - 4–6
 - metabolic mechanism 6–7
 - nutrition 7–8
 - plant biology 8
 - nuclear magnetic resonance platform
 - 25
 - precision medicine (PM)
 - BAs 148–150
 - biomarker discovery and implementation 147
 - biomarker testing 144
 - future aspect 150–151
 - herbal medicine 148–150
 - new era of medicine 144–145
 - potential biomarkers 146–147
 - precision biomarkers 145–146
 - principal component analysis 1, 2
 - screening metabolites 2, 3
 - urine metabolic profiles 87
 - YHS 87
 - microwave-assisted extraction (MAE)
 - 247
 - mild cognitive impairment (MCI) 136, 137
 - multivariate data analysis approach
 - CE-MS 48–49
 - clustering analysis 55
 - correlation analysis 54, 58
 - data analysis 53
 - heatmap visualization 54–55
 - K-means clustering analysis 54, 56
 - limitations and challenges 57–58
 - multivariate data analysis approach
 - 67
 - partial least squares discriminant analysis (PLS-DA) 53–54
 - PCA 53, 54
 - separation-based MS techniques
 - GC-MS 46
 - IM-MS 49
 - LC-MS 46–47
 - separation-free MS techniques
 - direct infusion-mass spectrometry (DI-MS) 49–50
 - DRAT 51
 - MALDI 50
 - mass spectrometry imaging (MSI)
 - 50–51
 - software/websites 51, 52, 66
 - tree clustering analysis 54, 57
 - trends and development of 59, 60
 - variable importance in projection (VIP)
 - 54
- n**
- natural products (NPs) 173, 176
 - biomarkers and targets 201
 - defined 199
 - herbal ingredients
 - analytical strategies for 205–206
 - in vitro and in vivo 206
 - mass spectrometry in
 - mechanisms analysis of action
 - 207–208
 - qualitative analysis 206–207
 - quantitative analysis 207
 - in metabolomics
 - capillary electrophoresis-mass spectrometry 203–204
 - challenges 204, 205
 - gas chromatography-mass spectrometry 203
 - ion mobility-mass spectrometry 204
 - liquid chromatography-mass spectrometry 203

- natural products (NPs) (*contd.*)
 mass spectrometry imaging 204
 MS-based metabolomics
 bioactive ingredients 208–212
 biochemical analysis 202
 databases 202
 small-molecule metabolites 202
 pharmacological effects 200–201
 screen bioactive 201
 neurodegenerative disorders, CNS 135
 NMR-MS 104–105
 non-alcoholic fatty liver diseases
 (NAFLD) 254
 non-targeted analysis of metabolites 24
 non-targeted lipidomics 225
 non-targeted metabolomics 98–100
 normal glucose regulation (NGR) 249
 nuclear magnetic resonance platform 25
 nutrition 7, 8
 nutritional metabolomics 7, 8
- o**
 Omics technologies 146
 osteoporosis (OP) 192
- p**
 paclitaxel 171
 Paris polyphylla var. yunnanensis
 (Franch) Hand Mazz (PPY) 175
 partial least squares discriminant analysis
 (PLS-DA) 53, 54
 pathway-enrichment analysis 87
 pattern recognition approach 69, 73
 perturbed pathways 135
 phenylalanine metabolism 115
 phosphatidylcholine 230
 phosphatidylethanolamine 230
 phospholipids 128
 plant biology 8
 Polygalae Radix 206
 precision medicine (PM)
 biomarker discovery and
 implementation 147
 future aspect 150–151
 herbal medicine 148–150
 new era of medicine 144–145
 potential biomarkers 146–147
 precision biomarkers 145–146
 principal component analysis (PCA) 53
 proline 117
- q**
 quality control (QC) samples 102
 quality markers (Q-markers) 193
- r**
 random forest 82, 83
 receiver operating characteristic (ROC)
 83, 86
 reserpine 199
 reversed-phase liquid
 chromatography-mass
 spectrometry (RPLC) 47
- s**
 saliva 36
 Schisandra chinensis (SC) 189
 screen bioactive natural products 201
 selection-significance analysis of
 microarrays (SAM) 83, 85
 Sennae Folium 199
 serum metabolomics strategy 201
 SFC-MS technique 24
 Shengmai San (SMS) 193
 Shotgun lipidomics 229
 Sijunzi decoction (SJZD) 175, 193, 209
 silibinin 171
 small-molecule metabolites 19, 20
Sophora flavescens (*S. flavescens*) 193
 sphingolipids 128
 spleen *qi* deficiency syndrome (SQDS)
 175, 193, 209
 supercritical fluid chromatography (SFC)
 22
 supercritical fluid chromatography-mass
 spectrometry 48
 Suxiao Jiuxin pill (SJP) 192
- t**
 targeted analysis of metabolites 24
 targeted lipidomics 224, 225, 249

- targeted metabolomics 68, 99
 - taxifolin 193
 - tissue homogenates 35–36
 - toxicity explorations 211
 - traditional Chinese medicine (TCM) syndrome 233
- u**
- ultra-high performance LC (UPLC) 47, 72, 176, 207
 - ultra-performance liquid chromatography coupled with mass spectrometry (UPLC/MS) 126
 - ultra-performance liquid chromatography-quadrupole time of flight-tandem MS (UPLC-Q/TOF-MS) 70
- v**
- variable importance in projection (VIP) 54, 59
- y**
- yang-huang syndrome (YHS) 87
 - Yinchenhao Tang (YCHT) 203, 211
- UNIFI™ platform 173, 174
 - untargeted lipidomics 248–249
 - untargeted metabolomics analysis 68, 201

